# TRI-SUCCESS - Tricuspid Regurgitation Study of the Unica™ Cross-Caval System for the Evaluation of Efficacy and Safety in Significant TR Subjects

Study · id `cardio:ct-nct07919366` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07919366](<https://clinicaltrials.gov/study/NCT07919366>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07919366

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 510 participants.

## Technical summary

Registry record NCT07919366. Randomized; no masking; primary purpose treatment. Start 2027-01-01 (anticipated); primary completion 2031-01-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 510 participants (planned count; ClinicalTrials.gov record NCT07919366, source copy `cardio:ctgov-nct07919366-2026-11-05`, retrieved 2026-11-18)
- Planned start: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT07919366, source copy `cardio:ctgov-nct07919366-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2031-01-01 (anticipated) (ClinicalTrials.gov record NCT07919366, source copy `cardio:ctgov-nct07919366-2026-11-05`, retrieved 2026-11-18)
- Completion: 2035-01-01 (anticipated) (ClinicalTrials.gov record NCT07919366, source copy `cardio:ctgov-nct07919366-2026-11-05`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07919366-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: TRI-SUCCESS - Tricuspid Regurgitation Study of the Unica™ Cross-Caval System for the Evaluation of Efficacy and Safety in Significant TR Subjects
- Acronym: TRI-SUCCESS
- Condition: Tricuspid Regurgitation
- Condition: Tricuspid Regurgitation Functional
- Intervention (Device): Innoventric Unica™ System
- Lead sponsor: Innoventric LTD
- Lead sponsor class: INDUSTRY
- Collaborator: Innoventric Inc.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Tricuspid regurgitation (`cardio:tricuspid-regurgitation`)

## Provenance

Content hash: 2638689810d5c6f4712a323942a5314afce4b8bfb629636527929c42d297a4c2
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
